Condition: Superficial Bladder Cancer · Non-muscle Invasive Bladder Cancer With Carcinoma in Situ · Sponsor: enGene, Inc.
This study will evaluate the safety and efficacy of intravesical administration of detalimogene (EG-70) in the bladder and its effect on bladder tumors in patients with NMIBC. This study study consists of two phases; a Phase 1 dose-escalation to establish safety and recommended the phase 2 dose, followed by a Phase 2 study to establish how effective the treatment is. The Study will include patients with: NMIBC with CIS for whom BCG therapy is unresponsive, and other high risk patients with NMIBC. A Substudy will include a surfactant bladder rinse prior to the instillation of detalimogene in patients with NMIBC with CIS for whom BCG therapy is unresponsive.
This description comes directly from the study's public registry record.
enGene clinical trials · +18572991097 · clinicaltrials@engene.com
Chris Tosone
Always discuss trial participation with your own doctor first.
| The University of Alabama at Birmingham Clinical Research Unit (CRU) | Birmingham, Alabama, United States | Recruiting |
| Mayo Clinic | Scottsdale, Arizona, United States | Recruiting |
| Urological Associates of South Arizona | Tucson, Arizona, United States | Completed |
| Arkansas Urology | Little Rock, Arkansas, United States | Recruiting |
| University of California - Irvine Medical Center | Irvine, California, United States | Recruiting |
| UC San Diego Moores Cancer Center | La Jolla, California, United States | Recruiting |
| USC/Norris Comprehensive Cancer Center | Los Angeles, California, United States | Recruiting |
| Tower Urology | Los Angeles, California, United States | Recruiting |
| Om Research | San Diego, California, United States | Recruiting |
| Colorado Clinical Research | Lakewood, Colorado, United States | Recruiting |
| The George Washington Medical Faculty Associates | Washington D.C., District of Columbia, United States | Recruiting |
| University of Florida | Jacksonville, Florida, United States | Recruiting |
+ 90 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT04752722